NEW YORK - A New York federal jury hearing the fourth Fosamax bellwether trial on Oct. 3 found that Merck's osteoporosis drug was not defectively designed and did not cause a plaintiff to develop osteonecrosis of the jaw (ONJ) (In Re: Fosamax Products Liability Litigation, MDL Docket No. 1789, No. 06-md-1789, Linda Secrest v. Merck & Co., Inc., No. 06-6692, S.D. N.Y.).
The jury in the U.S. District Court for the Southern District of New York answered "no" to the first question on the jury interrogatory: "Do you find that Fosamax was a defective product - in other words, unreasonably dangerous due to defective design - before July 1, 2004, and that its defective design was a legal cause of Mrs. [Linda] Secrest's osteonecrosis of the jaw ('ONJ')?"
In August, Judge John F. Keenan granted summary judgment to Merck on Secrest's other claims.
Secrest, a Florida resident, was prescribed Fosamax in June 1998 and says she continued using the osteoporosis drug until April 2005. She claims that she was diagnosed with ONJ, a condition in which the jaw bone fails to regenerate, particularly after oral surgery.
Whether Secrest took Fosamax continually during the seven-year period, when she was diagnosed with ONJ and whether she had ONJ were in dispute.
In a press release, Merck counsel Chilton Varner of King & Spalding in Atlanta said Secrest's medical problems caused her to develop jaw and dental problems. Varner said Secrest had a long history of invasive dental procedures and suffers from medical conditions that "inhibit the body's ability to heal."
Secrest's counsel, Timothy M. O'Brien of Levin, Papantonio, Thomas, Mitchell, Echsner & Proctor in Pensacola, Fla., told Mealey Publications "[W]e will appeal on at least two issues: one is the Court's pretrial ruling dismissing the failure to warn claim (leaving only the defective design claim) and two is the Court instructing the jury that a product is presumed non-defective if the FDA approved it. That one-two combination didn't leave the jury much choice in the matter."
Testimony began Sept. 8 and continued over 10 days. The jury went out on Sept. 27 and deliberated three days before returning its verdict Oct. 3.
[Editor's Note: Full coverage will be in the Oct. 6 issue of Mealey's Emerging Drugs & Devices. In the meantime, the blank verdict opinion is available at www.mealeysonline.com or by calling the Customer Support Department at 1-800-833-9844. Document #28-111006-024V. For all of your legal news needs, please visit www.lexisnexis.com/mealeys.]
Download the document now:
Lexis.com - Document #28-111006-024V
Mealeysonline.com - Document #28-111006-024V
For more information, call editor Tom Moylan at 215-988-7739, or email him at firstname.lastname@example.org.
Lexis.com subscribers may search all Mealey Publications.
Non-subscribers may search for Mealey Publications stories and documents at www.mealeysonline.com or visit www.Mealeys.com.
For more information about LexisNexis products and solutions, connect with us through our corporate site.